Edwards Lifesciences (EW) stock
NYSE
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $61.6B
- As of Nov 13, 2026
- P/E
- 60.23x
- Trailing twelve months
- P/B
- 5.67x
- Latest reported equity
- P/S
- 9.23x
- Trailing twelve months
- ROE
- 9.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $61.6B
- As of Nov 13, 2026
- P/E
- 60.23x
- Trailing twelve months
- P/B
- 5.67x
- Latest reported equity
- P/S
- 9.23x
- Trailing twelve months
- ROE
- 9.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
60.23x
P/B
5.67x
P/S
9.23x
Earnings and dividend metrics▾
Earnings
EPS
$1.78
Earnings per share
BPS
$18.89
Book value per share
ROE
9.4%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $1.78 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $18.89 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 9.4%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 10.5% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.55B+10.5%
$1.35B
Jul–Sep '24
$1.55B
Jul–Sep '25
$1.72B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share increased 6.0% from the same quarter a year earlier.
- Revenue increased 10.5% from the same quarter a year earlier.
- Operating income decreased 2.6% from the same quarter a year earlier.
- Net income increased 5.8% from the same quarter a year earlier.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Dahl Andrew M.SVP, Corporate Controller · Nov 13, 2026Shares withheld for taxes101 shares · $11KAvg. price $105.814,606 shares held after
- Lippis Daniel J.CVP, TAVR · Nov 10, 2026Open-market sale619 shares · $65KAvg. price $104.2540,034 shares held after
- Lippis Daniel J.CVP, TAVR · Nov 10, 2026Option exercise619 shares · $45KAvg. price $72.6840,653 shares held after
- BOBO DONALD E JRCVP,Strategy/Corp Development · Nov 9, 2026Open-market sale48,900 shares · $5.0MAvg. price $103.053422,798 shares held after
- Zovighian Bernard JCEO · Nov 9, 2026Open-market sale23,100 shares · $2.4MAvg. price $103.0208
Show 2 price lots
- 13,916 shares × $102.7803$1.4M
- 9,184 shares × $103.3851$949K
- BOBO DONALD E JRCVP,Strategy/Corp Development · Nov 9, 2026Option exercise48,900 shares · $3.6MAvg. price $72.6871,698 shares held after
- Zovighian Bernard JCEO · Nov 9, 2026Option exercise23,100 shares · $1.7MAvg. price $72.68121,945 shares held after
- Lippis Daniel J.CVP, TAVR · Oct 8, 2026Open-market sale619 shares · $53KAvg. price $85.6540,034 shares held after
- Lippis Daniel J.CVP, TAVR · Oct 8, 2026Option exercise619 shares · $45KAvg. price $72.6840,653 shares held after
- Markowitz WayneCVP, JAPAC · Sep 14, 2026Shares withheld for taxes568 shares · $48KAvg. price $84.3719,371 shares held after
- Dahl Andrew M.SVP, Corporate Controller · Sep 13, 2026Shares withheld for taxes253 shares · $21KAvg. price $84.3714,615 shares held after
- Lippis Daniel J.CVP, TAVR · Sep 11, 2026Open-market sale619 shares · $54KAvg. price $87.5140,034 shares held after
- Lippis Daniel J.CVP, TAVR · Sep 11, 2026Option exercise619 shares · $45KAvg. price $72.6840,653 shares held after
- Chopra DaveenCVP, TMTT, Surgical & IHFM · Sep 11, 2026Shares withheld for taxes398 shares · $35KAvg. price $86.7743,926 shares held after
- Markowitz WayneCVP, JAPAC · Sep 11, 2026Shares withheld for taxes355 shares · $31KAvg. price $86.7719,939 shares held after
- Dahl Andrew M.SVP, Corporate Controller · Aug 31, 2026Open-market sale544 shares · $50KAvg. price $91.05514,868 shares held after
- Bruls AnnetteCVP, EMEACLA · Aug 28, 2026Open-market sale2,644 shares · $238KAvg. price $89.9817,984 shares held after
- Chopra DaveenCVP, TMTT, Surgical & IHFM · Aug 26, 2026Open-market sale31,800 shares · $2.9MAvg. price $91.0201
Show 2 price lots
- 30,646 shares × $90.9922$2.8M
- 1,154 shares × $91.7614$106K
- Markowitz WayneCVP, JAPAC · Aug 26, 2026Open-market sale1,240 shares · $113KAvg. price $91.46520,294 shares held after
- Chopra DaveenCVP, TMTT, Surgical & IHFM · Aug 26, 2026Option exercise31,800 shares · $2.3MAvg. price $72.6876,124 shares held after
- Lippis Daniel J.CVP, TAVR · Aug 11, 2026Open-market sale619 shares · $57KAvg. price $92.0340,034 shares held after
- Lippis Daniel J.CVP, TAVR · Aug 11, 2026Option exercise619 shares · $45KAvg. price $72.6840,653 shares held after
- Markowitz WayneCVP, JAPAC · Jul 30, 2026Open-market sale146 shares · $13KAvg. price $86.033821,534 shares held after
- Markowitz WayneCVP, JAPAC · Jul 28, 2026Open-market sale9,628 shares · $819KAvg. price $85.0621,680 shares held after
- Markowitz WayneCVP, JAPAC · Jul 28, 2026Option exercise9,628 shares · $713KAvg. price $74.0231,308 shares held after
- Zovighian Bernard JCEO · Jul 27, 2026Open-market sale2,921 shares · $245KAvg. price $83.93428,916 shares held after
- Zovighian Bernard JCEO · Jul 27, 2026Gift639 shares · $0Avg. price $0
Show 2 price lots
- 320 shares × $0$0
- 320 shares × $0$0
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QEdwards Lifesciences said net sales for the first 9 months of 2026 were $5.1 billion, an increase of $607.1 million from the same period of 2025, driven mainly by sales of its TAVR and TMTT products.Published Nov 4, 2026 · Filed Nov 4, 2026Read the summary →
- AI summary8-KThe company said net sales for Q3 2026 rose to $1,715.5 million, up 10.5% from $1,553.1 million a year earlier (11.2% on a constant currency basis). TAVR sales grew 8.0%, and TMTT sales grew 44.3%.Published Nov 4, 2026 · Filed Nov 4, 2026Read the summary →
- AI summary8-KEdwards Lifesciences said stockholders approved the amendment and restatement of its Long-Term Stock Incentive Compensation Program at the 2026 Annual Meeting of Stockholders. The total number of shares of Edwards common stock available for issuance under the program increased by 7,000,000 shares to a new total share limit of 341,500,000 shares.Published Oct 1, 2026 · Filed May 8, 2026Read the summary →
- Edwards Lifesciences said net sales for the first 9 months of 2026 were $5.1 billion, an increase of $607.1 million from the same period of 2025, driven mainly by sales of its TAVR and TMTT products.Read the full analysis →
- The company said net sales for Q3 2026 rose to $1,715.5 million, up 10.5% from $1,553.1 million a year earlier (11.2% on a constant currency basis). TAVR sales grew 8.0%, and TMTT sales grew 44.3%.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Edwards Lifesciences (EW) stock information
NYSE
Edwards Lifesciences (EW) is listed on NYSE. Its market capitalization is about $61.6B. On trailing-twelve-month earnings the P/E ratio is 60.23, and the P/B ratio is 5.67. Return on equity is 9.4%. These figures are computed in-house from official filings and are reference information only.
Edwards Lifesciences — frequently asked questions
- What is the P/E ratio of Edwards Lifesciences (EW)?
- On a trailing-twelve-month basis, EW trades at a P/E ratio of 60.23. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Edwards Lifesciences?
- EW has a market capitalization of about $61.6B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.